Drug Trial Radar · NCT06878664
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
166
Planned (sponsor's estimate)
Start
Jun 12, 2025
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- Grupo Espanol de Tumores NeuroendocrinosAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
- First posted
- Mar 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized Phase II/late phase I de-escalation clinical trial with approved investigational medicinal products in new use condition, low intervention. Disease under study Patients with unresectable or metastatic, slowly progressive, well-differentiated (Grade1 and Grade2), somatostatin receptor-positive midgut neuroendocrine tumors (GEP-NETs). It is planned to randomize 166 patients with a histologically confirmed diagnosis of slowly progressive grade 1 or grade 2 advanced midgut neuroendocrine tumors (NETs) candidates to receive 177Lu-Dotatate targeted radioligand therapy (RLT). Patients are required to have SSTR+ disease, as evidenced on somatostatin receptor imaging. Patients will be randomized into two arms: 1. control arm: regimen 177Lu-Dotatate every 8 weeks (q8w) 2. experimental arm: regimen 177Lu-Dotatate every 16 weeks (q16w) Research hypothesis: Less intensive somatostatin-receptor (SST) targeted radioligand therapy (RLT) (7.4 GBq/cycle 177Lu-Dotatate every 16 weeks x 4 cycles) is associated with less severe hematological toxicities and may mitigate the risk to develop therapy-related myeloid neoplasms (t-MN) with similar antitumor efficacy in slowly growing gastrointestinal grade 1-2 NETs.
Conditions
- Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
Interventions
177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.Drug
Treatment with 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks 177Lu-Dotatate, a radiopharmaceutical medicine which is an somatostatin analogue derived from octreotide that complexes via DOTA with non-carrier added (n.c.a) 177Lu radioconjugate. 177Lu-Dotatate will be supplied as a 370 MBq/mL solution for infusion. One mL of solution contains 370 MBq The total amount of radioactivity per single-dose vial is 7 400 MBq at the date and time of infusion. Given the fixed volumetric activity of 370 MBq/mL at the date and time of calibration, the volume of the solution in the vial ranges between 20.5 and 25.0 mL in order to provide the required amount of radioactivity at the date and time of infusion of lutetium (177Lu) oxodotreotide at the date and time of calibration.
177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.Drug
Treatment with 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles 177Lu-Dotatate, a radiopharmaceutical medicine which is an somatostatin analogue derived from octreotide that complexes via DOTA with non-carrier added (n.c.a) 177Lu radioconjugate. Synonyms are: 177Lu-DOTA0-Tyr 3-Octreotate, 177Lu-DOTATE LUTATHERA, lutetium (177Lu) oxodotreotide 177Lu-Dotatate will be supplied as a 370 MBq/mL solution for infusion One mL of solution contains 370 MBq The total amount of radioactivity per single-dose vial is 7 400 MBq at the date and time of infusion. Given the fixed volumetric activity of 370 MBq/mL at the date and time of calibration, the volume of the solution in the vial ranges between 20.5 and 25.0 mL in order to provide the required amount of radioactivity at the date and time of infusion of lutetium (177Lu) oxodotreotide at the date and time of calibration.
Amino acid solutionDrug
Renal protection starting 30 minutes before RLT and lasting 4 hours (iv) amino acid solution of 14.4-20 g of lysine and 14.9-20.7 g of arginine in 1 to 2 liters of solution)
Lanreotide (Autogel formulation) or Octreotide LARDrug
Long-acting standard doses of SSA (Lanreotide autogel 120 mg subcutaneous (sc) or Octreotide LAR 30 mg im, starting 24h after RLT and every 4 weeks during RLT (q16w interval SSA administration should be adjusted to RLT administrations so that SSA is always given 24h after each RLT dose and at least 4 weeks prior to next RLT administration cycle) and q4w following last RLT administration until disease progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Grade 2-5 hematological toxicityTime frame: Throughout the study period, from initiation of treatment with RLT up to 24 months
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Centre François BACLESSE
Caen, Caen, France · Recruiting
Chu Dijon
Dijon, Dijon, France · Recruiting
Hospital Center University De Lille
Lille, Lille, France · Recruiting
Hospices Civiles de Lyon
Lyon, Lyon, France · Recruiting
Institut Paoli Calmette
Marseille, Marseille, France · Not yet recruiting
Hopital BEAUJON
Clichy, Paris, France · Recruiting
Hopital COCHIN
Paris, Paris, France · Recruiting
Institute Gustave Roussy
Villejuif, Paris, France · Recruiting
Centre Eugène MARQUIS
Rennes, Rennes, France · Not yet recruiting
Hospital Universitari Vall d'Hebrón
Barcelona, Barcelona, Spain · Recruiting
Instituto Catalán de Oncología - Hospital Duran i Reynals
L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting
Hospital Universitario de Burgos
Burgos, Castille and León, Spain · Recruiting
Hospital Virgen de las Nieves de Granada
Granada, Granada, Spain · Recruiting
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, Spain · Recruiting
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Spain · Recruiting
Hospital 12 de Octubre
Madrid, Madrid, Spain · Recruiting
Hospital Universitario La Paz
Madrid, Madrid, Spain · Recruiting
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain · Recruiting
Hospital Universitario Virgen del Rocío
Seville, Sevilla, Spain · Recruiting
Hospital Clínico de Valencia
Valencia, Valencia, Spain · Recruiting
Hospital Universitario y Politécnico La Fe
Valencia, Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.